Thanks to an innovative consortium between Rutgers University, Princeton University and the New Jersey Institute of Technology, New Jersey residents will have greater access to the most advanced clinical trials and medical breakthroughs. The consortium is called the New Jersey Alliance for Clinical and Translational Science (NJ-ACTS) and most recently the National Institutes of Health (NIH) announced a $33-million grant infusion into this dynamic new initiative.

What is the New Jersey Alliance for Clinical and Translational Science? (NJ-ACTS)

NJ-ACTS has been set up to advance clinical and translational science to develop new therapies and treatments and improve health and health care in The Garden State. The consortium—coordinated by Rutgers Biomedical and Health Sciences, NJACTS includes Rutgers and Princeton Universities, NJ Institute for Technology (NJIT), medical, nursing, dental and public health schools, hospitals, community health centers, outpatient practices, industry policymakers and health information exchanges. Representing a unique collaboration and combination of institutions, NJACTS commits to community engagement, ensuring that New Jersey state residents are partners in research through patient advocacy and community partnerships.

NJ-ACTS supports this clinical translational research via a series of services, expertise, and financial resources, not to mention the facilitation of collaboration among partners—offering training and workforce development while improving the public’s understanding of science and research.

Leadership

NJ-ACTS leadership includes a board of directors, executive committee and steering committee.  Follow the link to learn more.         

Recent Event

Recently consortium participants and stakeholders met to discuss the future of scientific and clinical trial innovation in the state. Again, these innovations will result from the recent $33 million grant. In association with the event, Reynold Panettieri, vice chancellor for translational medicine and science and director of the Rutgers Institute for Translational Medicine and Science, commented “We aim to shorten the time it takes to get innovative drugs in the market, train the next generation of translational scientists, engage patients and communities and integrate special and underserved populations, advance use of big data information and increase the quality and efficacy in translational research.”                                                                                                                                                              The Evolution of a Revolution in Health

Panelists used the term “The Evolution of a Revolution in Health” to discuss potential solutions for unmet health care needs in the Garden State and ways in which public-private partnership can develop cutting-edge treatments.”

Call to Action: Interested in contacting NJ-ACTS? See the contact web page

Source: Newswise

Pin It on Pinterest